LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

17.23 0.23

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

17.23

Max

17.45

Galvenie mērījumi

By Trading Economics

Ienākumi

-70M

-67M

Pārdošana

-2.1M

20M

P/E

Sektora vidējais

48.528

105.69

Dividenžu ienesīgums

0.48

Peļņas marža

-330.585

Darbinieki

243

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-7.57% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.37%

Nākamie ieņēmumi

2025. g. 1. dec.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-5.6M

346M

Iepriekšējā atvēršanas cena

17

Iepriekšējā slēgšanas cena

17.23

Ziņu noskaņojums

By Acuity

50%

50%

160 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 14. nov. 17:45 UTC

Peļņas
Galvenie tirgus virzītāji

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

2025. g. 14. nov. 17:31 UTC

Peļņas
Galvenie tirgus virzītāji

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

2025. g. 15. nov. 18:03 UTC

Peļņas

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

2025. g. 15. nov. 15:43 UTC

Peļņas

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

2025. g. 15. nov. 12:00 UTC

Peļņas

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

2025. g. 15. nov. 09:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 15. nov. 09:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 15. nov. 00:08 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

2025. g. 14. nov. 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

2025. g. 14. nov. 23:02 UTC

Tirgus saruna

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

2025. g. 14. nov. 22:35 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

2025. g. 14. nov. 22:32 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

2025. g. 14. nov. 22:29 UTC

Peļņas

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

2025. g. 14. nov. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

2025. g. 14. nov. 21:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 14. nov. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

2025. g. 14. nov. 20:27 UTC

Tirgus saruna

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

2025. g. 14. nov. 20:23 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

2025. g. 14. nov. 20:17 UTC

Iegādes, apvienošanās, pārņemšana

Several State Attorneys General Oppose Railroad Merger -- WSJ

2025. g. 14. nov. 19:29 UTC

Tirgus saruna
Peļņas

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

2025. g. 14. nov. 18:44 UTC

Tirgus saruna
Peļņas

Disney's Growth Now Hinges More on ESPN -- Market Talk

2025. g. 14. nov. 18:27 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 14. nov. 18:27 UTC

Tirgus saruna

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

2025. g. 14. nov. 18:20 UTC

Tirgus saruna

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

2025. g. 14. nov. 17:20 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 14. nov. 17:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 14. nov. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 14. nov. 16:51 UTC

Tirgus saruna

Starbucks Gets Holiday Sales Lift -- Market Talk

2025. g. 14. nov. 16:48 UTC

Tirgus saruna

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

2025. g. 14. nov. 16:38 UTC

Tirgus saruna

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-7.57% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD  -7.57%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

160 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat